JP2022513933A5 - - Google Patents

Info

Publication number
JP2022513933A5
JP2022513933A5 JP2021534641A JP2021534641A JP2022513933A5 JP 2022513933 A5 JP2022513933 A5 JP 2022513933A5 JP 2021534641 A JP2021534641 A JP 2021534641A JP 2021534641 A JP2021534641 A JP 2021534641A JP 2022513933 A5 JP2022513933 A5 JP 2022513933A5
Authority
JP
Japan
Prior art keywords
disorders
compound according
disorder
status epilepticus
salt form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513933A (ja
JP7645797B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066923 external-priority patent/WO2020131918A1/en
Publication of JP2022513933A publication Critical patent/JP2022513933A/ja
Publication of JP2022513933A5 publication Critical patent/JP2022513933A5/ja
Application granted granted Critical
Publication of JP7645797B2 publication Critical patent/JP7645797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534641A 2018-12-17 2019-12-17 有機化合物 Active JP7645797B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780703P 2018-12-17 2018-12-17
US62/780,703 2018-12-17
PCT/US2019/066923 WO2020131918A1 (en) 2018-12-17 2019-12-17 Organic compounds

Publications (3)

Publication Number Publication Date
JP2022513933A JP2022513933A (ja) 2022-02-09
JP2022513933A5 true JP2022513933A5 (cg-RX-API-DMAC7.html) 2022-12-23
JP7645797B2 JP7645797B2 (ja) 2025-03-14

Family

ID=71100855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534641A Active JP7645797B2 (ja) 2018-12-17 2019-12-17 有機化合物

Country Status (11)

Country Link
US (1) US12325726B2 (cg-RX-API-DMAC7.html)
EP (1) EP3897656A4 (cg-RX-API-DMAC7.html)
JP (1) JP7645797B2 (cg-RX-API-DMAC7.html)
KR (1) KR102931436B1 (cg-RX-API-DMAC7.html)
CN (1) CN113226326B (cg-RX-API-DMAC7.html)
AU (1) AU2019406803B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011765A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121636A1 (cg-RX-API-DMAC7.html)
IL (1) IL283960B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007142A (cg-RX-API-DMAC7.html)
WO (1) WO2020131918A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
US20230416300A1 (en) * 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
DK2168585T3 (da) * 2005-06-09 2012-02-27 Euro Celtique Sa Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) * 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US20230416300A1 (en) 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds

Similar Documents

Publication Publication Date Title
JP2023539125A5 (cg-RX-API-DMAC7.html)
JP2023527575A5 (cg-RX-API-DMAC7.html)
JP2021519267A5 (cg-RX-API-DMAC7.html)
RU2012127770A (ru) Полициклические соединения и способы их применения
CA2636324A1 (en) Cycloalkylamines as monoamine reuptake inhibitors
JP2022535093A (ja) 重水素化された又は部分的に重水素化されたn,n-ジメチルトリプタミン化合物を含む治療用組成物
KR100630981B1 (ko) 알파-2-델타-단백질에 대한 친화성을 갖는 아미노산
JP2017531020A5 (cg-RX-API-DMAC7.html)
JP2018104454A5 (cg-RX-API-DMAC7.html)
JP2018505898A5 (cg-RX-API-DMAC7.html)
RU2007119585A (ru) Производные рапамицина и их применение при лечении неврологических заболеваний
US5552418A (en) Trisubstituted Naphthylalkylamides
JP2009527462A5 (cg-RX-API-DMAC7.html)
RU2009143104A (ru) Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии
RU2008100019A (ru) Способ лечения чрезмерной дневной сонливости (варианты)
WO2020143762A1 (en) Ketamine pamoate and use thereof
EP4457222A2 (en) Nitric oxide releasing prodrugs of mda and mdma
JP2023509798A5 (cg-RX-API-DMAC7.html)
JP2024531437A5 (cg-RX-API-DMAC7.html)
JP2018508592A5 (cg-RX-API-DMAC7.html)
JP2024507638A5 (cg-RX-API-DMAC7.html)
JP2024532249A5 (cg-RX-API-DMAC7.html)
JP2023550543A5 (cg-RX-API-DMAC7.html)
JP2014518552A5 (cg-RX-API-DMAC7.html)
RU2016132574A (ru) Органические соединения